Clinical collaboration announced between Telix Pharmaceuticals and Radboud University Medical Center

Telix Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic targeted radiopharmaceuticals, has recently announced a clinical collaboration with the Radboud University Medical Center (Radboudumc).

Pre-Phase III bridging/dosimetry study
The institutions will cooperate in various projects related to 89Zr-girentuximab (TLX-250), Telix’s pipeline product for imaging of clear cell renal cell cancer (ccRCC) via PET. Among others, Radboudumc will co-lead and advise the pre-Phase III bridging/dosimetry study and the Phase III trial for TLX-250, as well as the IMPACT-RCC study (NCT02228954), which aims to establish how molecular imaging can be used to measure therapeutic treatment response in metastatic kidney cancer.

Dr. Andreas Kluge, Telix Co-Founder and CMO, stated: “Radboudumc has been a clinical leader in the use of 89Zr-Girentuximab (TLX-250) in the clinic and their patient experience underpins much of the confidence we have in the imaging agent, particularly the change in isotope to a radiometal for superior image quality, sensitivity and patient convenience. We have worked closely with Radboudumc as part of activating our clinical activity for TLX-250 in Europe.”

Cutting-edge technology for pre-clinical and clinical imaging
Professor Peter Mulders, Chairman of the Department of Urology at Radboudumc, noted: “We are pleased to be working with Telix to progress this very important technology from a clinical perspective. This international collaboration lays the foundation for the completion of product development of 89Zr-Girentuximab and we are delighted to be part of bringing this technology to renal cancer patients in the Netherlands and beyond.”
Within the collaboration, Telix will fund a clinical fellowship position at the Department of Radiology and Nuclear Medicine of the Radboudumc, a role that shall oversee the various activities around this mutual effort. In addition, the Radboudumc Technology Center imaging facility will also be a key partner, stepping in with its cutting-edge technology and expertise for pre-clinical and clinical imaging.

References

  • Telix Pharma website: www.telixpharma.com
  • Radboud University Medical Center website: Radboudumc.